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None of the four main epitopes on the HIV-1 envelope protein (CD4 binding site, N160 glycan in V1V2, N332 glycan 
in V3, and MPER; highlighted in warm colors and bold font), nor four additional sites (N276 glycan in C2, N611 glycan 
in C-C loop, N88 glycan in C1, K169 in V1V2; highlighted in blue colors and small font), are strongly targeted by 
neutralizing antibody responses in HIV-1 superinfected individuals from a Kenyan cohort. while the 4 main epitopes 
have been shown to be the dominant targets of broad and potent neutralizing antibody responses in individuals with a 
single infection from other cohorts, the absence of such a response in HIV-1 superinfected individuals suggests that 
their neutralizing antibody responses may be collectively mediated by diverse, polyclonal antibodies. 
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Development of a human immunodeficiency virus-1 (HIV-1) vaccine that elicits neutralizing 
antibodies (Nabs) that are both potent and broad remains a major public health goal. However, one 
of the main challenges of HIV-1 vaccine design is the diversity of HIV-1 subtypes that are currently 
circulating worldwide. One scenario that holds great potential to inform future vaccine design is HIV-
1 superinfection (SI), defined as one person receiving sequential infections from different source 
partners. Previous studies in Dr. Julie Overbaugh’s Laboratory (Human Biology Division) showed 
that a cohort of 12 superinfected women from Mombasa (Kenya) developed broader and more 
potent Nab responses than singly infected individuals (Cortez et al., 2012). However, it remains 
unclear whether SI and singly infected individuals differed in other ways, such as the specificity of 
the antibody response. A new Fred Hutch follow-up study by the Overbaugh lab, led by former 
graduate student Dr. Valerie Cortez and published in PLOS Pathogens, addressed this question by 
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mapping the antibody response of 21 superinfected women onto epitopes (parts of proteins or other 
antigens that bind antibodies) of the HIV-1 Envelope protein.  
Previous studies on singly infected individuals with broad Nabs mapped the bulk of their neutralizing 
activity onto four major epitopes on the HIV-1 Envelope protein: the membrane proximal external 
region (MPER), the CD4 binding site, residues in the V1/V2 region, and the V3 loop (see figure). The 
study began by assaying post-SI plasma from all 21 women. MPER-specific antibodies were 
infrequently detected, and such antibodies appeared to arise over a year following SI. Next, the 
authors tested for CD4-binding site-specific antibodies in post-SI plasma by comparing binding with 
an Envelope core protein engineered to prominently display the CD4-binding site versus a mutant 
protein that harbored a deletion that abrogates the binding of CD4-specific antibodies. One out of the 
21 women had antibodies that bound the wild-type Envelope more strongly than the mutant, but this 
individual’s CD4-binding site-specific antibodies did not demonstrate neutralizing activity. Nabs that 
target either the V1/V2 region or the V3 loop require a glycan (a sugar moiety on a protein) at 
specific positions and comparisons of wild-type versus glycan deficient Envelopes failed to provide 
strong evidence for glycan-specific Nabs. 
 Beyond these four epitopes, several additional epitopes have been linked to newly characterized 
Nabs. To investigate further, the authors also engineered point mutations in these novel epitopes. 
Again, the antibodies targeted to the newly discovered epitopes did not appear to be major drivers of 
the SI response. Finally, the researchers employed computational analyses to corroborate the 
functional data, which confirmed that none of the 21 women developed a Nab response that could 
be ascribed with high confidence to a single known epitope. "Since none of neutralizing antibody 
responses from the 21 superinfected individuals strongly targeted any of the epitopes tested in our 
study, this may suggest that HIV-1 superinfection leads to a broad, polyclonal response that 
collectively mediates their ability to neutralize diverse HIV-1 envelopes Continual study of the virus-
antibody interplay in HIV-1 superinfected individuals may yield insights to how we can design 
sequential immunizations that elicit a diverse, polyclonal antibody response capable of recognizing 
globally diverse HIV-1 subtypes," said Dr. Cortez. In conclusion, a combination of functional and 
computational analyses enabled the authors to characterize the epitope targets of Nabs linked to SI 
for the first time.  
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